| Cat. No. |
Product Name |
Information |
| PC-38178 |
Ensitrelvir
3CLpro inhibitor
|
Ensitrelvir (S-217622, S217622) is the first oral, non-covalent, non-peptidic SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate with biochemical IC50 of 13 nM, antiviral EC50 of 0.37 uM. |
| PC-35231 |
GC376
3CLpro inhibitor
|
GC376 (GC-376) is a broad-spectrum antiviral agent that inhibits 3C or 3C-like proteases (3Cpro or 3CLpro) of picornaviruses, noroviruses, and coronaviruses with IC50 of 0.96 (MD145), 0.82 (TGEV) and 0.2 uM (HRV) in FRET protease assays. |
| PC-28371 |
1’-cyanocytidine
SARS-CoV-2 RdRp inhibitor
|
1'-cyanocytidine (CNC) is a nontoxic, next-generation nucleoside analog that displays submicromolar inhibition of SARS-CoV-2 replication with EC50 of 0.6-2.1 uM, targeting the viral RNA-dependent RNA polymerase (RdRp). |
| PC-28225 |
SM142
Mpro/CatL inhibitor
|
SM142 is a potent, selective peptidomimetic dual inhibitor of SARS-CoV-2 main protease (MPro) and host cathepsin L (CatL) with IC50 of 1.8 uM and 0.145 uM respectively. |
| PC-28224 |
SM141
Mpro/CatL inhibitor
|
SM141 is a potent, selective peptidomimetic dual inhibitor of SARS-CoV-2 main protease (MPro) and host cathepsin L (CatL) with IC50 of 0.9 uM and 0.06 uM respectively. |
| PC-27892 |
mCMX110
SARS-CoV-2 Mpro inhibitor
|
mCMX110 is a potent, selective, orally bioavailable SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 35 nM. |
| PC-26986 |
ACE2 inhibitor MB-32
ACE2 inhibitor
|
MB‑32 is a specific, allosteric inhibitor of angiotensin‑converting enzyme 2 (ACE2) with KD of 7.078 and 3.997 uM in SPR and BLI assays, selectively disrupts binding of SARS‑CoV‑2 spike receptor‑binding domain to ACE2, MB-32 is a potent and specific broad-spectrum entry inhibitor of pan-sarbecoviruses. |
| PC-26746 |
CG-0988
SARS-CoV-2 3CLpro inhibitor
|
CG-0988 is a potent, covalent SARS-CoV-2 3C-like protease (3CLpro) inhibitor with IC50 of 8.5 nM, demonstrates excellent antiviral activity with EC50 of 4.0 nM against Omicron EG.5.1. |
| PC-26549 |
SARS-CoV-2 entry inhibitor S22
RBD-ACE2 inhibitor
|
SARS-CoV-2 entry inhibitor S22 is a potent, SARS-CoV-2-specific entry inhibitor that neutralizes BA.2 and subsequent Omicron variants, blocks RBD-ACE2 interaction. |
| PC-26541 |
SR-A-174
SARS-CoV-2 Mpro inhibitor
|
SR-A-174 is a highly potent, covalent inhibitor of SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 60 nM. |
| PC-26481 |
PoMA-10
SARS-CoV-2 Spike-ACE2 inhibitor
|
PoMA-10 is an effective inhibitor of SARS-CoV-2 Spike-ACE2 interaction, shows direct binding to ACE2 without affecting enzymatic activity, inhibits SARS-CoV-2 infection in vero cells with IC50 of 23.5 uM. |
| PC-26476 |
pan-Coronavirus fusion inhibitor EK1
Coronaviruses fusion inhibitor
|
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species, potently inhibits SARS-CoV-2, competitively binds to heptad repeat 1 in the spike protein, blocking the formation of the six-helix bundle (6-HB) between viral HR1 and HR2 regions required for viral-cellular membrane fusion. |
